CCO Infectious Disease Podcast

Key Decisions in HIV Care: Considerations for Long-Acting Injectable PrEP

Episode Summary

Listen as Jason Schafer, PharmD, MPH, shares key considerations for using long-acting injectable cabotegravir for PrEP, including management of missed dosing, stopping PrEP, and screening for HIV while receiving PrEP.

Episode Notes

In this episode, Jason Schafer, PharmD, MPH, explores key considerations for the use of long-acting injectable pre-exposure prophylaxis (PrEP).

- Listen as he gives his perspectives on:

- The FDA approval of long-acting cabotegravir for PrEP

- Healthcare professionals’ clinical concerns with long-acting injectable antiretroviral therapy

- Considerations for long-acting cabotegravir as PrEP

• Dosing and administration
• Managing missed doses
• Discontinuation
• Delays in HIV diagnoses found in the HPTN 083 study in men

- CDC recommendations for HIV screening while receiving PrEP

Presenter:

Jason Schafer, PharmD, MPH
Professor and Vice Chair
Jefferson College of Pharmacy
Thomas Jefferson University
Philadelphia, Pennsylvania  

Follow along with the slides at: 
https://bit.ly/3wugMOC

See the entire program at: 
https://bit.ly/3q2DlGd